August 17, 2016 11:43 AM EDT
R&D

Pro­to­cols: In­di­v­ior claims PhI­II suc­cess, points to 2017 FDA OK; In­Vi­vo touts an­oth­er pa­tient re­sponse in spinal study

John Carroll

Editor & Founder

The UK’s In­di­v­ior (LON: IN­DV) got a boost to­day af­ter an­nounc­ing that its Phase III study of a month­ly dose of buprenor­phine was …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times